FDA Drug Recalls

Recalls / Class II

Class IID-0369-2023

Product

Aripiprazole Tablets, USP 20 mg Rx Only, packaged as, a) 30-count bottle, NDC 16729-282-10, UPC 3 16729 28210 9; b) 100-count bottle, NDC 16729-282-01, UPC 3 16729 28201 7; Manufactured for: Accord Healthcare, Inc., Durham, NC 27703. Manufactured by: Intas Pharmaceuticals Limited, Pharmez, Ahmedabad-382 213. India

Brand name
Aripiprazole
Generic name
Aripiprazole
Active ingredient
Aripiprazole
Route
Oral
NDCs
16729-278, 16729-279, 16729-280, 16729-281, 16729-282, 16729-283
FDA application
ANDA206251
Affected lot / code info
Batches: a) P2100787, P2100788, Exp. Date 1/31/2024; P2104736, Exp. Date 6/30/2024; P2105492, Exp. Date 8/31/2024; P2107172, P2107175, Exp. Date 10/31/2024; P2203043, Exp. Date 5/31/2025; b) P2104086 Exp. Date 6/30/2024, P2205370 Exp. 8/31/2025;

Why it was recalled

CGMP Deviations: recalling drug products following an FDA inspection.

Recalling firm

Firm
Accord Healthcare, Inc.
Notification channel
Letter
Type
Voluntary: Firm initiated
Address
1009 Slater Rd Ste 210B, N/A, Durham, North Carolina 27703-8446

Distribution

Quantity
170,448 bottles
Distribution pattern
United States including Puerto Rico and Canada

Timeline

Recall initiated
2023-02-07
FDA classified
2023-03-02
Posted by FDA
2023-03-08
Terminated
2024-04-22
Status
Terminated

Source: openFDA Drug Enforcement endpoint. Recall record D-0369-2023. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.